U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H39N6O8P
Molecular Weight 618.6184
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SELATOGREL

SMILES

CCCCOC(=O)N1CCN(CC1)C(=O)[C@H](CP(O)(O)=O)NC(=O)C2=NC(=NC(=C2)N3CC[C@@H](C3)OC)C4=CC=CC=C4

InChI

InChIKey=FYXHWMQPCJOJCH-GMAHTHKFSA-N
InChI=1S/C28H39N6O8P/c1-3-4-16-42-28(37)33-14-12-32(13-15-33)27(36)23(19-43(38,39)40)30-26(35)22-17-24(34-11-10-21(18-34)41-2)31-25(29-22)20-8-6-5-7-9-20/h5-9,17,21,23H,3-4,10-16,18-19H2,1-2H3,(H,30,35)(H2,38,39,40)/t21-,23-/m0/s1

HIDE SMILES / InChI

Molecular Formula C28H39N6O8P
Molecular Weight 618.6184
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

ACT-281959 (molecular weight 850.9 g/mol), the di-ester prodrug of ACT-246475 (molecular weight 618.6 g/mol), was developed to improve absorption after oral dosing and is rapidly converted by esterases in vivo to ACT-246475 in two-steps via the formation of ACT-409100 (molecular weight 734.7 g/mol), the mono-ester prodrug. ACT-281959 is a novel potent and selective P2Y12 receptor antagonist with a wider therapeutic window. ACT-281959 showed antithrombotic efficacy after oral administration in the rat ferric chloride model. ACT-281959 entered clinical studies in healthy volunteers. ACT-281959 had been in phase I clinical trials by Actelion for the treatment of thrombosis. But there is no development reported for this study recently.

Approval Year

PubMed

PubMed

TitleDatePubMed

Sample Use Guides

The study had a double-blind, randomized, ascending single-dose design with an oral formulation F1 (i.e., ACT-281959 or placebo) (Part I) and an open-label, randomized, 3-period, crossover design comparing exploratory formulations of ACT-281959 (F2) 70 mg and ACT-246475 (dF) 50 mg to F1 70 mg (Part II). In Part I, doses up to 1,000 mg were tested in 40 healthy subjects.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Thu Jul 06 16:03:37 UTC 2023
Edited
by admin
on Thu Jul 06 16:03:37 UTC 2023
Record UNII
6DPK7O4PR7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SELATOGREL
INN  
Official Name English
1-PIPERAZINECARBOXYLIC ACID, 4-((2R)-2-(((6-((3S)-3-METHOXY-1-PYRROLIDINYL)-2-PHENYL-4-PYRIMIDINYL)CARBONYL)AMINO)-1-OXO-3-PHOSPHONOPROPYL)-, 1-BUTYL ESTER
Systematic Name English
selatogrel [INN]
Common Name English
4-((R)-2-((6-((S)-3-METHOXYPYRROLIDIN-1-YL)-2-PHENYLPYRIMIDINE-4-CARBONYL)AMINO)-3-PHOSPHONOPROPIONYL)PIPERAZINE-1-CARBOXYLIC ACID BUTYL ESTER
Systematic Name English
ACT-246475
Code English
Code System Code Type Description
PUBCHEM
59534142
Created by admin on Thu Jul 06 16:03:37 UTC 2023 , Edited by admin on Thu Jul 06 16:03:37 UTC 2023
PRIMARY
DRUG BANK
DB15163
Created by admin on Thu Jul 06 16:03:37 UTC 2023 , Edited by admin on Thu Jul 06 16:03:37 UTC 2023
PRIMARY
INN
10877
Created by admin on Thu Jul 06 16:03:37 UTC 2023 , Edited by admin on Thu Jul 06 16:03:37 UTC 2023
PRIMARY
SMS_ID
100000183604
Created by admin on Thu Jul 06 16:03:37 UTC 2023 , Edited by admin on Thu Jul 06 16:03:37 UTC 2023
PRIMARY
CAS
1159500-34-1
Created by admin on Thu Jul 06 16:03:37 UTC 2023 , Edited by admin on Thu Jul 06 16:03:37 UTC 2023
PRIMARY
NCI_THESAURUS
C166930
Created by admin on Thu Jul 06 16:03:37 UTC 2023 , Edited by admin on Thu Jul 06 16:03:37 UTC 2023
PRIMARY
FDA UNII
6DPK7O4PR7
Created by admin on Thu Jul 06 16:03:37 UTC 2023 , Edited by admin on Thu Jul 06 16:03:37 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
IN-VITRO
Scientific Literature
Related Record Type Details
ACTIVE MOIETY
Official Title: A Single-center, Double-blind, Randomized, Placebo-controlled, Single-ascending Oral Dose and Food Interaction Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects Purpose: Study Part I is a single-ascending dose study. Healthy male subjects to be included in the study and randomized in 6 dose groups, Groups A-F (8 subjects per group). Of the 8 subjects per group, 6 subjects receive the investigational drug and 2 subjects receive matching placebo. Study Part II is a 3-period, crossover, single dose study. Nine healthy male subjects to be enrolled in one group (Group G). Each subject to receive 2 different formulations of the prodrug and one formulation of the active drug in a randomized sequence.